当前位置:首页 - 行情中心 - 热景生物(688068) - 财务分析 - 利润表

热景生物

(688068)

  

流通市值:28.20亿  总市值:28.20亿
流通股本:9226.88万   总股本:9226.88万

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入406,916,772.66307,007,061.27202,939,171.053,556,551,569.15
营业收入406,916,772.66307,007,061.27202,939,171.053,556,551,569.15
二、营业总成本401,559,759.11263,337,262.01150,641,590.422,297,525,641.45
营业成本146,092,036.85103,979,48861,148,919.261,646,278,958.75
税金及附加3,393,554.272,355,534.67995,573.1310,020,030.3
销售费用130,802,159.0177,340,824.4435,146,104.69268,917,635.98
管理费用53,121,058.8833,526,587.2727,357,373.61214,660,148.96
研发费用99,168,834.0568,117,516.9633,864,932.96191,138,698.15
财务费用-31,017,883.95-21,982,689.33-7,871,313.23-33,489,830.69
其中:利息费用---2,318,284.34
其中:利息收入13,195,584.7719,366,191.749,336,284.8531,119,794.93
加:公允价值变动收益-16,563,336.07-6,231,071.014,046,575.817,516,978.18
加:投资收益-11,010,386.26405,746.091,263,390.193,397,417.9
资产处置收益-65,476.25-65,476.25-65,476.26-338,564.43
资产减值损失(新)5,471,151.2435,904.167,905,970.14-182,221,104.35
信用减值损失(新)12,385,138.12739,547.61114-10,161,125.57
其他收益50,201,494.247,025,963.593,169,047.7113,633,765.67
营业利润平衡项目000.010
四、营业利润45,775,598.5385,580,413.4568,617,202.231,090,853,295.1
加:营业外收入2,034,630.881,898,645.2711,830.971,680,709.55
减:营业外支出2,660,871.761,391,341.7271,137.6417,313,328.79
利润总额平衡项目0000
五、利润总额45,149,357.6586,087,716.9369,257,895.561,075,220,675.86
减:所得税费用-1,786,127.29,691,700.2413,162,066.12150,103,687.82
六、净利润46,935,484.8576,396,016.6956,095,829.44925,116,988.04
持续经营净利润-76,396,016.6956,095,829.44-
归属于母公司股东的净利润54,381,071.2884,768,666.8758,884,119.48944,736,633.48
少数股东损益-7,445,586.43-8,372,650.18-2,788,290.04-19,619,645.44
(一)基本每股收益0.610.950.6610.33
(二)稀释每股收益0.610.950.6610.28
八、其他综合收益-97,183.48-348,880.58-269,443.22
归属于母公司股东的其他综合收益-103,287.77-352,610.12-268,499.79
九、综合收益总额46,838,301.3776,047,136.1156,095,829.44925,386,431.26
归属于母公司股东的综合收益总额54,277,783.5184,416,056.7558,884,119.48945,005,133.27
归属于少数股东的综合收益总额-7,439,482.14-8,368,920.64-2,788,290.04-19,618,702.01
公告日期2023-10-312023-08-302023-04-282023-04-28
审计意见(境内)标准无保留意见
TOP↑